The global cell and gene therapy thawing equipment market is witnessing notable growth, driven by the increasing adoption of these therapies for treating various diseases and disorders. Cell and gene therapy thawing equipment are specialized devices used to thaw frozen cell and gene therapy products safely and efficiently. These therapies often require cryopreservation to maintain their stability and viability. Thawing equipment is designed to carefully thaw these frozen products without damaging their structure or reducing effectiveness. Cell and gene therapies require careful thawing processes to maintain efficacy and viability, creating a demand for specialized thawing equipment. Factors such as the growing investment in research and development activities, the rising number of clinical trials for cell and gene therapies, and the expanding biopharmaceutical industry are fueling the market's expansion. Moreover, technological advancements in thawing equipment, such as automated and programmable systems development, are further boosting market growth. Overall, the global cell and gene therapy thawing equipment market is expected to continue growing, driven by the increasing demand for these innovative therapies and the advancements in thawing technology.
The Global Cell And Gene Therapy Thawing Equipment Market size was valued at USD 823.62 million in 2023 and is projected to reach USD 2,382.62 million by 2031, with a CAGR of 14.20% during the forecast period of 2024 to 2031.
Below are the Top Five Cell and Gene Therapy Thawing Equipment Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
merck KGAA
|
Merck KGaA, a leading science and technology company, is a prominent player in the cell and gene therapy thawing equipment market. The company offers a range of products and solutions tailored to meet the specific needs of cell and gene therapy applications, including thawing equipment designed to maintain the integrity and viability of these sensitive therapies. Merck KGaA's market presence in cell and gene therapy thawing equipment is strengthened by its strong focus on innovation and research. The company continually invests in developing advanced thawing solutions that address the market's evolving requirements. Moreover, Merck KGaA's strategic partnerships and collaborations with key industry players further enhance its position in the market. These partnerships allow the company to leverage complementary technologies and expertise to develop cutting-edge thawing equipment that meets the highest quality and performance standards.
|
|
Africa, Asia, Europe, Latin America, North America, Oceania
|
In October 2020, Merck KGaA launched the VirusExpress Lentiviral Production Platform. The rise of the Virus Express Lentiviral Production Platform would result in overcoming the challenges in lentiviral production, and reducing the process development by 40%. It would provide lucrative opportunities for curative treatments.
|
|
2.
|
eppendorf AG
|
Eppendorf AG, a renowned provider of high-quality laboratory equipment and consumables, has a notable presence in the cell and gene therapy thawing equipment market. The company offers a range of innovative thawing solutions designed to meet the specific needs of cell and gene therapy applications, ensuring the safe and efficient thawing of sensitive biological materials.
Eppendorf AG's thawing equipment is known for its precision, reliability, and ease of use, making it a preferred choice among researchers and clinicians in cell and gene therapy. The company's thawing products are designed to maintain the integrity and viability of biological materials, ensuring optimal results in cell and gene therapy applications. Furthermore, Eppendorf AG's strong focus on research and development enables it to continually innovate and improve its thawing solutions to meet the market's evolving needs. The company's commitment to quality and innovation has helped it establish a strong reputation in the market.
|
|
North America, Africa, Asia-Pacific, Europe
|
In August 2020, Eppendorf AG conducted a virtual lab exhibition for biotechnology instruments and consumables. This would result in increased awareness about the use of thawing instruments.
|
|
3.
|
Sartorius AG
|
Sartorius AG, a leading laboratory and bioprocessing equipment provider, is a prominent player in the cell and gene therapy thawing equipment market. The company's thawing equipment is known for its precision, reliability, and advanced technology, making it a preferred choice among researchers and clinicians in cell and gene therapy. The company's thawing products are designed to maintain the integrity and viability of biological materials, ensuring optimal results in cell and gene therapy applications. Furthermore, Sartorius AG's strong focus on innovation and research enables it to continually develop and improve its thawing solutions to meet the market's evolving needs. The company's commitment to quality and innovation has helped it establish a strong reputation in the cell and gene therapy thawing equipment market.
|
|
North America, Middle East and Africa, Asia-Pacific, Europe
|
In July 2021, Sartorius AG acquired cell culture specialist Xell AG. This acquisition is anticipated to strengthen the company's business growth in the coming years.
|
|
4.
|
cytiva (A subsidiary of danaher corporation)
|
Cytiva, formerly GE Healthcare Life Sciences, is a major player in the cell and gene therapy thawing equipment market. The company offers a range of innovative thawing solutions designed to meet the specific needs of cell and gene therapy applications, ensuring the safe and efficient thawing of sensitive biological materials. Its strong focus on innovation and research enables it to continually develop and improve its thawing solutions to meet the market's evolving needs. The company's commitment to quality and innovation has helped it establish a strong reputation in the cell and gene therapy thawing equipment market.
|
|
North America, Middle East and Africa, Europe
|
In July 2021, Cytiva and Pall Corporation invested USD 1.5 billion for two years to come across the growing demands for Biotechnology Solutions. The investment between the two companies would lead to a rise in customer demand and the inauguration of new sites in the U.S. and the U.K. for cell therapeutic models. The company is planning to hire more than 2000 associates.
|
|
5.
|
Barkey
|
Barkey GmbH & Co. KG is a reputable manufacturer of innovative medical devices, including thawing equipment for cell and gene therapy applications. The company's thawing solutions are designed to meet the specific requirements of these sensitive therapies, ensuring the safe and efficient thawing of biological materials.
Its thawing equipment is known for its reliability, precision, and user-friendly design, making it a preferred choice among researchers and clinicians in the cell and gene therapy field. The company's products are engineered to maintain the integrity and viability of biological materials, thereby optimizing the outcomes of cell and gene therapy procedures. Innovation is at the core of Barkey's approach, driving the development of new thawing solutions that cater to the market's evolving needs. The company's commitment to quality and technological advancement has established it as a trusted provider of thawing equipment for cell and gene therapy applications.
|
|
Europe
|
|
Conclusion
The global cell and gene therapy thawing equipment market is witnessing significant growth, driven by the increasing adoption of these therapies and the growing need for specialized thawing solutions. Market players are actively expanding their product portfolios and investing in research and development to innovate new thawing equipment that meets the specific requirements of cell and gene therapies. Companies also focus on strategic collaborations and partnerships to enhance their market presence and expand their customer base. With the continuous advancements in technology and the rising demand for cell and gene therapies, market players are expected to accelerate their growth further and solidify their positions in the market.
